Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma

Pituitary

Volumn 14, Issue 4, 2011, Pages 351-357

  Fusco, Alessandra ^a   Lugli, Francesca ^a   Sacco, Eugenia ^a   Tilaro, Laura ^a   Bianchi, Antonio ^a   Angelini, Flavia ^a   Tofani, Anna ^b   Barini, Angela ^a   Lauriola, Libero ^a   Maira, Giulio ^a   Pontecorvi, Alfredo ^a   De Marinis, Laura ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cabergoline; Octreoscan; Octreotide; Prolactinoma; Somatostatin receptor

Indexed keywords

CABERGOLINE; DESMOPRESSIN; HYDROCORTISONE; KI 67 ANTIGEN; LEVOTHYROXINE SODIUM; OCTREOTIDE; PENTETREOTIDE IN 111; PROLACTIN; PROTEIN P53; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TESTOSTERONE;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; BRAIN SCINTISCANNING; CANCER INVASION; CASE REPORT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES INSIPIDUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; ENDOCRINE FUNCTION TEST; HEMIANOPIA; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOGONADISM; HYPOPITUITARISM; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; NERVE COMPRESSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; PERIMETRY; PRIORITY JOURNAL; PROLACTINOMA; UNILATERAL BLINDNESS;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; ERGOLINES; HUMANS; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTINOMA; TREATMENT OUTCOME;

EID: 80053903952     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-008-0162-y     Document Type: Article

References (34)

1. FF Casanueva ME Molitch JA Schlechte R Abs V Bonert MD Bronstein T Brue P Cappabianca AM Colao R Fahlbusch H Fideleff M Hadani P Kelly D Kleinberg E Laws J Marek M Scanlon LG Sobrinho JA Wass A Giustina 2006 Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrinol (Oxf) 65 265 273 10.1111/j.1365-2265.2006.02562.x 10.1111/j.1365-2265.2006.02562.x (Pubitemid 44079693)
2. C Missale SR Nash SW Robinson M Jaber MG Caron 1998 Dopamine receptors: from structure to function Physiol Rev 78 189 225 9457173 1:CAS:528: DyaK1cXptlOjtg%3D%3D (Pubitemid 28070979)
3. A Di Sarno ML Landi P Cappabianca F Di Salle FW Rossi R Pivonello C Di Somma AG Faggiano G Lombardi AM Colao 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy J Clin Endocrinol Metab 86 5256 5261 10.1210/jc.86.11.5256 11701688 10.1210/jc.86.11.5256 1:CAS:528:DC%2BD3MXos1KqsL4%3D (Pubitemid 33070245)
4. ME Molitch 2005 Pharmacological resistance in prolactinoma patients Pituitary 8 43 52 10.1007/s11102-005-5085-2 16411068 10.1007/s11102-005-5085-2 1:CAS:528:DC%2BD28XksVOgtw%3D%3D (Pubitemid 44680085)
5. MP Gillam ME Molitch G Lombardi AM Colao 2006 Advances in the treatment of prolactinomas Endocr Rev 27 485 534 10.1210/er.2005-9998 16705142 10.1210/er.2005-9998 1:CAS:528:DC%2BD28XpvVelurY%3D (Pubitemid 44213229)
6. I Pellegrini R Rasolonjanahary G Gunz P Bertrand S Delivet CP Jedynak C Kordon F Peillon P Jaquet A Enjalbert 1989 Resistance to bromocriptine in prolactinomas J Clin Endocrinol Metab 69 500 509 2760167 10.1210/jcem-69-3-500 1:STN:280:DyaL1MzktVOrsA%3D%3D (Pubitemid 19221218)
7. DK Hamilton ML Vance PT Boulos ER Laws 2005 Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists Pituitary 8 53 60 10.1007/s11102-005-5086-1 16411069 10.1007/s11102-005-5086-1 (Pubitemid 44680086)
8. K Thapar K Kovacs BW Scheithauer L Stefaneanu E Horwath PJ Pernicone D Murray ER Laws Jr 1996 Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody Neurosurgery 38 99 106 10.1097/00006123-199601000-00024 8747957 10.1097/00006123-199601000-00024 1:STN:280:DyaK28zlsVShsw%3D%3D (Pubitemid 26002389)
9. E Delgrange G Sassolas G Perrin M Jan J Trouillas 2005 Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance Acta Neurochir (Wien) 147 751 758 10.1007/s00701-005- 0498-2 10.1007/s00701-005-0498-2 1:STN:280:DC%2BD2MzitVOjtg%3D%3D (Pubitemid 40853793)
10. BW Scheithauer TA Gaffey RV Lloyd TJ Sebo KT Kovacs E Horvath O Yapicier WF Young Jr FB Meyer T Kuroki DL Riehle ER Laws Jr 2006 Pathobiology of pituitary adenomas and carcinomas Neurosurgery 59 341 353 10.1227/01.NEU. 0000223437.51435.6E 16883174 10.1227/01.NEU.0000223437.51435.6E (Pubitemid 44325877)
11. Y Greenman S Melmed 1994 Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage J Clin Endocrinol Metab 79 724 729 10.1210/jc.79.3.724 7521350 10.1210/jc.79.3.724 1:STN:280:DyaK2czlvVSksg%3D%3D (Pubitemid 24286392)
12. H Murabe A Shimatsu C Ihara H Mizuta Y Nakamura I Nagata H Kikuchi K Nakao 1996 Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription- polymerase chain reaction J Neuroendocrinol 8 605 610 10.1111/j.1365-2826.1996. tb00695.x 8866248 10.1111/j.1365-2826.1996.tb00695.x 1:CAS:528: DyaK28XltFWht70%3D (Pubitemid 26270913)
13. P Jaquet L Quafik A Saveanu G Gunz F Fina H Dufour MD Culler JP Moreau A Enjalbert 1999 Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas J Clin Endocrinol Metab 84 3268 3276 10.1210/jc.84.9.3268 10487698 10.1210/jc.84.9.3268 1:CAS:528:DyaK1MXlvVGktrk%3D (Pubitemid 30646955)
14. E Thodou G Kontogeorgos D Theodossiou M Pateraki 2006 Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas J Clin Pathol 59 274 279 10.1136/jcp.2005.026914 16505278 10.1136/jcp.2005.026914 1:STN:280:DC%2BD287hslykuw%3D%3D (Pubitemid 43344889)
15. SWJ Lamberts EP Krenning JC Reubi 1991 The role of somatostatin and its analogues in the diagnosis and treatment of tumours Endocr Rev 12 450 482 1684746 10.1210/edrv-12-4-450 1:CAS:528:DyaK38Xht1SqsbY%3D
16. M Schmidt K Scheidhauer C Luyken E Voth G Hildebrant N Klung H Schicha 1998 Somatostatin receptor imaging in intracranial tumours Eur J Nucl Med 25 675 686 10.1007/s002590050269 9662588 10.1007/s002590050269 1:CAS:528: DyaK1cXktlyju7w%3D (Pubitemid 28377029)
17. A Colao S Lastoria D Ferone P Varrella P Marzullo R Pivonello G Cerbone W Acampa M Salvatore G Lombardi 1999 The pituitary uptake of 111In-DPTA-DPhe1- octreotide in the normal pituitary and in pituitary adenomas J Endocrinol Invest 22 176 183 10219884 1:CAS:528:DyaK1MXisVSrt70%3D (Pubitemid 29158636)
18. MJ Acosta-Gomez MA Muros JM Llamas-elvira A Ramirez S Ortega G Sabatel C Ramos A a Aguilar 2005 The role of somatostatin receptor scintigraphy in patients with pituitari adenoma or post-surgical recurrent tumours Br J Radiol 78 110 115 10.1259/bjr/51245688 15681321 10.1259/bjr/51245688 1:STN:280:DC%2BD2M%2Flt1alsg%3D%3D (Pubitemid 40277725)
19. I Shimon X Yan JE Taylor MH Weiss MD Culler S Melmed 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas J Clin Invest 100 2386 2392 10.1172/JCI119779 9410919 10.1172/JCI119779 1:CAS:528:DyaK2sXnt1GgsbY%3D (Pubitemid 27500164)
20. LJ Hofland WW de Herder HA Visser-Visselaar C van Uffelen M Waaijers J Zuyderwijk P Uitterlinden MJM Kros PM van Koetsveld WJ Lamberts 1997 Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release on a small subgroup of pituitary- and islet cell tumours J Clin Endocrinol Metab 82 3011 3018 10.1210/jc.82.9.3011 9284735 10.1210/jc.82.9.3011 1:CAS:528:DyaK2sXlvFemt7g%3D (Pubitemid 27385664)
21. M Ishibashi T Yamaji 1985 Mechanism of the inhibitory action of dopamine and somatostatin on prolactin secretion from human lactotrophs in culture J Clin Endocrinol Metab 60 599 606 2579087 10.1210/jcem-60-3-599 1:CAS:528: DyaL2MXhsVemtr8%3D (Pubitemid 15133867)
22. LJ Hofland J van der Hoek PM van Koetsveld WW de Herder M Waaijers D Sprij-Mooji C Bruns G Weckbecker R Feelders AJ van der Lely A Beckers WJ Lamberts 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro J Clin Endocrinol Metab 89 1577 1585 10.1210/jc.2003-031344 15070915 10.1210/jc.2003-031344 1:CAS:528:DC%2BD2cXjt1els7c%3D (Pubitemid 38507905)
23. RD Murray K Kim SG Ren I Lewis G Weckbecker C Brun S Melmed 2004 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion J Clin Endocrinol Metab 89 3027 3032 10.1210/jc.2003-031319 15181094 10.1210/jc.2003-031319 1:CAS:528:DC%2BD2cXmtlKjsLY%3D (Pubitemid 38766404)
24. SW Lamberts M Zweens JG Klijn CC van Vroonhoven SZ Stefanko E Del Pozo 1986 The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly Clin Endocrinol (Oxf) 25 201 212 10.1111/j.1365-2265.1986.tb01683.x 10.1111/j.1365-2265.1986.tb01683.x 1:CAS:528:DyaL28XlsVKltrY%3D (Pubitemid 16046359)
25. MD Bronstein M Knoepfelmacher B Liberman R Marino Jr OA Germek AV Shally 1987 Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia Horm Metab Res 19 271 274 10.1055/s-2007- 1011796 2887502 10.1055/s-2007-1011796 1:STN:280:DyaL2szgs1aqsQ%3D%3D (Pubitemid 17082615)
26. S Grottoli V Gasco F Broglio R Baldelli F Ragazzoni F Gallenca A Mainolfi F Prodam G Muccioli E Ghigo 2006 Cortistatin-17 and Somatostatin-14 display the same effects on growth hormone, prolactin and insulin secretion in patients with acromegaly or prolactinoma J Clin Endocrinol Metab 91 1595 1599 10.1210/jc.2005-1837 16449338 10.1210/jc.2005-1837 1:CAS:528: DC%2BD28XjvFOktb8%3D
27. M Rocheville DC Lange U Kumar SC Patel RC Patel YC Patel 2000 Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity Science 288 154 157 10.1126/science.288.5463.154 10753124 10.1126/science.288.5463.154 1:CAS:528:DC%2BD3cXisVGku7o%3D (Pubitemid 30203051)
28. A Gruszka SG Ren J Dong MD Culler S Melmed 2007 Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules Endocrinology 148 6107 6114 10.1210/en.2007-0378 17656461 10.1210/en.2007-0378 1:CAS:528:DC%2BD2sXhsVers7rI (Pubitemid 350146153)
29. A Fusco G Gunz P Jaquet H Dufour AL Germanetti MD Culler A Barlier A Saveanu 2008 Somatostatinergic ligands in dopamine-sensitive and resistant prolactinomas Eur J Endocrinol 158 595 603 10.1530/EJE-07-0806 18426817 10.1530/EJE-07-0806 1:CAS:528:DC%2BD1cXmtlanurw%3D (Pubitemid 351639596)
30. R Zanettini A Antonini G Gatto R Gentile S Tesei G Pezzoli 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 39 46 10.1056/NEJMoa054830 17202454 10.1056/NEJMoa054830 1:CAS:528:DC%2BD2sXitlCgsQ%3D%3D (Pubitemid 46041752)
31. R Schade F Andersohn S Suissa W Haverkamp E Garbe 2007 Dopamine agonists and the risk of cardiac valve regurgitation N Engl J Med 356 29 38 10.1056/NEJMoa062222 17202453 10.1056/NEJMoa062222 1:CAS:528: DC%2BD2sXitlCgsg%3D%3D (Pubitemid 46041751)
32. M Kars V Delgado ER Holman RA Feelders JW Smit JA Romijn JJ Bax AM Pereira 2008 Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma J Clin Endocrinol Metab 93 9 3348 3356 10.1210/jc.2007-2658 18559921 10.1210/jc.2007-2658 1:CAS:528:DC%2BD1cXhtFChurvE
33. A Wakil A Rigby A Clark S Atkin 2008 Low dose cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease Eur J Endocrinol 159 4 R11 R14 18625690 10.1530/EJE-08-0365 1:CAS:528:DC%2BD1cXhtlSrtb3O Epub 2008 Jul 14
34. A Colao M Galderisi A Di Sarno M Pardo M Gaccione M D'Andrea E Guerra R Pivonello G Lerro G Lombardi 2008 Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline J Clin Endocrinol Metab 93 10 3777 3784 10.1210/jc.2007-1403 18682513 10.1210/jc.2007-1403 1:CAS:528:DC%2BD1cXht1Gmur%2FM